Pulmonology Pulmonology
Pulmonol 2018;24:231-40 - Vol. 24 Num.4 DOI: 10.1016/j.pulmoe.2018.02.003
Original article
Pulmonary hypertension: Real-world data from a Portuguese expert referral centre
A. Gomesa, C. Cruza, J. Rochaa, M. Ricardoa, M. Vicenteb, A. Meloc, M. Santosc,d, L. Carvalhoa,c, F. Gonçalvesa,c, A. Reisc,,
a Internal Medicine Service, Medicine Department, Centro Hospitalar do Porto – Hospital de Santo António, Porto, Portugal
b Department of Health Sciences, University of Aveiro, Aveiro, Portugal
c Pulmonary Vascular Disease Unit, Medicine Department, Centro Hospitalar do Porto Hospital de Santo António, Porto, Portugal
d Cardiology Service, Medicine Department, Centro Hospitalar do Porto – Hospital de Santo António, Porto, Portugal
Received 29 August 2017, Accepted 04 February 2018
Abstract
Background

Pulmonary hypertension (PH) is a heterogeneous, debilitating condition with highly relevant impact on functional capacity, quality of life, and life-expectancy.

Objectives

This study aims to provide long-term data on the Portuguese PH population, by characterising the clinical presentation, evolution, and outcomes of PH patients in a specialised referral centre.

Methods

Retrospective analysis of a cohort of 101 patients with pre-capillary PH (pcPH) referenced to an expert tertiary care referral centre in northern Portugal from 2002 to 2013. Diagnosis was confirmed by right heart catheterisation (RHC). PH classification followed consensus criteria from the 5th World Symposium in Nice, 2013.

Results

The most frequent causes of pcPH were Group 1 PH – pulmonary arterial hypertension (PAH) (54.4%) and Group 4 PH – Chronic thromboembolic pulmonary hypertension (CTEPH) (25.7%); importantly, 17.8% of patients presented PH associated with multiple aetiologies. Targeted therapy was used in 91.1% of patients (48.5% combination therapy). 1-, 3-, and 5-year survival was estimated at 86.6%, 76.7%, and 64.1%, respectively. Survival was significantly better for those ≤40 years old (10.5 vs. 6.4 years; P=0.003) and for women with I/HPAH (9.3 vs. 4.5 years; P=0.039).

Conclusions

This study provides long-term, real-world data for the management of PAH and CTEPH in Portugal and demonstrates the importance of dedicated electronic medical records and well defined clinical management protocols for better patient outcomes. Patients presented mostly with intermediate or high risk of mortality, which suggests delayed diagnosis and highlights the need to increase awareness among clinicians.

Keywords
Pulmonary hypertension, Pulmonary arterial hypertension, Survival, Portuguese population, Cohort, Real-world data
Pulmonol 2018;24:231-40 - Vol. 24 Num.4 DOI: 10.1016/j.pulmoe.2018.02.003
Cookies Policy
x
To improve our services and products, we use cookies (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.